| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1Calcium Research Laboratories, Department of Medicine, McGill University Health Centre; 2Division of Geriatric Medicine, McGill University; and 3Centre Hospitalier de l’Université de Montréal, Research Centre, Hôpital Saint-Luc, Montreal, Quebec, Canada
Submitted 26 April 2004 ; accepted in final form 23 November 2004
Recent studies suggest that vitamin D signaling regulates bone formation. However, the overall effect of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] on bone turnover in vivo is still unclear. In this study, our aim was to examine the effect of 1,25(OH)2D3 on bone turnover in SAM-P/6, a hormone-independent mouse model of senile osteoporosis characterized by a decrease in bone formation. Male and female 4-mo-old SAM-P/6 mice were treated with 1,25(OH)2D3 (18 pmol/24 h) or vehicle for a period of 6 wk, and a group of age- and sex-matched nonosteoporotic animals was used as control. Bone mineral density (BMD) at the lumbar spine increased rapidly by >30 ± 5% (P < 0.001) in 1,25(OH)2D3-treated SAM-P/6 animals, whereas BMD decreased significantly by 18 ± 2% (P < 0.01) in vehicle-treated SAM-P/6 animals and remained stable in control animals during the same period. Static and dynamic bone histomorphometry indicated that 1,25(OH)2D3 significantly increased bone volume and other parameters of bone quality as well as subperiosteal bone formation rate compared with vehicle-treated SAM-P/6 mice. However, no effect on trabecular bone formation was observed. This was accompanied by a marked decrease in the number of osteoclasts and eroded surfaces. A significant increase in circulating bone formation markers and a decrease in bone resorption markers was also observed. Finally, bone marrow cells, obtained from 1,25(OH)2D3-treated animals and cultured in the absence of 1,25(OH)2D3, differentiated more intensely into osteoblasts compared with those derived from vehicle-treated mice cultured in the same conditions. Taken together, these findings demonstrate that 1,25(OH)2D3 acts simultaneously on bone formation and resorption to prevent the development of senile osteoporosis.
1,25-dihydroxyvitamin D3; osteoporosis; bone turnover; histomorphometry; bone markers
This article has been cited by other articles:
|
|
 |
|
  J. C. McCann and B. N. Ames Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J, April 1, 2008; 22(4): 982 - 1001. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Li, K. L. Svenson, L. R. B. Donahue, L. L. Peters, and G. A. Churchill Relationships of dietary fat, body composition, and bone mineral density in inbred mouse strain panels Physiol Genomics, March 14, 2008; 33(1): 26 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Duque As a Matter of Fat: New Perspectives on the Understanding of Age-Related Bone Loss IBMS BoneKEy, April 1, 2007; 4(4): 129 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. O'Brien, R. L. Jilka, Q. Fu, S. Stewart, R. S. Weinstein, and S. C. Manolagas IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E784 - E793. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
